31. TNG1412. Humanized agonistic ANTI-cd28 monoclonal antibody. Investigator’s Brochure. TeGenero. 19.12.2006. (Электронный ресурс) URL: www.circare.org/foia5/ tgn1412investigatorbrochure.pdf (дата обращения: 31.01.2021).
32. Hanke T. Lessons from TGN1412. Lancet. 2006 Nov 4;368(9547):1569-70; author reply 1570. doi: 10.1016/S0140-6736(06)69651-7. www.ncbi.nlm.nih.gov/ pubmed/17084746 (дата обращения: 31.01.2021).
33. Vessillier S., Eastwood D., Fox B. et al. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials – Whole blood cytokine release assays are poorly predictive for www.ncbi.nlm.nih.gov/pubmed/25960173 (дата обращения: 31.01.2021).
34. Eastwood D., Findlay L., Poole S. et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 2010 Oct;161(3):512-26. doi: 10.1111/j.1476–5381.2010.00922.x. www.ncbi.nlm.nih.gov/pubmed/20880392 (дата обращения: 31.01.2021).
35. EudraCTN°: 2015-001799-24 Clinical Study Protocol N° BIA-102474-101. Biotrial Code: lBIAL35. Version 1.2. Date: 01 July 2015. BIAL – Portela & ca, S.A. (Электронный ресурс) URL: http://ansm.sante.fr/content/download/84681/1069223/ version/1/file/protocole_BIAL_102474+101-22012016131259.pdf (дата обращения: 31.01.2021).
36. Touraine M. Accident grave dans le cadre d’un essai clinique. Conference de presse Rennes. Vendredi 15 janvier 2016. Public le 15.01.16. (Электронный ресурс) URL: https://solidarites-sante.gouv.fr/archives/archives-presse/archives-discours/ article/accident-grave-dans-le-cadre-d-un-essai-clinique-intervention-de-marisol (дата обращения: 31.01.2021).
37. Casassus B. France investigates drug trial disaster. Lancet. 2016 Jan 23;387(10016):326. doi: 10.1016/S0140-6736(16)00154-9. https://pubmed.ncbi. nlm.nih.gov/26842439 (дата обращения: 31.01.2021).
38. January 16, 2016. Expert reaction to French drug trial – reports of one patient dying and five others in hospital and of the Paris prosecutor’s office having opened an investigation into what happened. Science Media Centre. (Электронный ресурс) URL: www.sciencemediacentre.org/expert-reaction-to-french-drug-trial-reports-of-one-patient-dying-and-five-others-in-hospital-and-of-the-paris-prosecutors-office-having-opened-an-investigation-into-what-happened (дата обращения: 31.01.2021).
39. Kaur R.J., Singh S., Sidhu P., Sharma P.K. TGN-1412 and BIA-2474 Trials with Tragic End: Lessons Learnt To Make Clinical Trials Safer. Rev Recent Clin Trials. 2018;13(4):252–256. doi: 10.2174/1574887113666180521093529. www.ncbi.nlm. nih.gov/pubmed/29779485 (дата обращения: 31.01.2021).
40. Новосельскш С.А. Смертность и продолжительность жизни в Pocciu. Петроградъ, 1916. (Электронный ресурс) URL: www.demoscope.ru/weekly/knigi/novoselskij/ novoselskij_1916.pdf (дата обращения: 31.01.2021).
41. IV. Эволюция смертности по причинам смерти. (Электронный ресурс) URL: www.demoscope.ru/weekly/knigi/shkol/glava4.pdf (дата обращения: 31.01.2021).
42. Брифинг ВОЗ о воздействии потребления табака на здоровье и экономику стран, входящих в евразийскую рабочую группу. Сентябрь 2013 г. (Электронный ресурс) URL: www.who.int/tobacco/economics/meetings/ru_eurasia_profile.pdf (дата обращения: 31.01.2021).
43. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/ S0140-6736(14)61682-2. www.ncbi.nlm.nih.gov/pubmed/25530442 (дата обращения: 31.01.2021).
44. No authors listed. Corrigendum to: Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2019 Jan 7;40(2):189. doi: 10.1093/ eurheartj/ehy342. www.ncbi.nlm.nih.gov/pubmed/29846568 (дата обращения: 31.01.2021).
45. Prochaska J.H., Arnold N., Junger C. et al. [Prevention of cardiovascular diseases] [Article in German]. Herz. 2018 Feb;43(1):87-100. doi: 10.1007/s00059-017-4669-8. www.ncbi.nlm.nih.gov/pubmed/29335743 (дата обращения: 31.01.2021).
46. Li Y., Pan A., Wang D.D. et al. Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population. Circulation. 2018 Jul 24;138(4):345–355. doi: 10.1161/CIRCULATIONAHA.117.032047. www.ncbi.nlm.nih.gov/pubmed/29712712 (дата обращения: 31.01.2021).
47. Таблица SCORE риска смерти от сердечно-сосудистого заболевания в ближайшие 10 лет для стран Европы с высоким риском. (Электронный ресурс) URL: https://commons.wikimedia.org/wiki/File: SCORE2007.png (дата обращения: 29.01.2021).
48. Torzewski J., Torzewski M., Bowyer D.E. et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1386-92. doi: 10.1161/01.atv.18.9.1386. www.ncbi.nlm.nih.gov/pubmed/9743226 (дата обращения: 31.01.2021).
49. Ridker P.M., Danielson E., Fonseca F.A. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. www.ncbi.nlm.nih.gov/ pubmed/18997196 (дата обращения: 31.01.2021).
50. Hsia J., MacFadyen J.G., Monyak J., Ridker P.M. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011 Apr 19;57(16):1666-75. doi: 10.1016/j.jacc.2010.09.082. www.ncbi.nlm.nih.gov/ pubmed/21492764 (дата обращения: 31.01.2021).
51. Yebyo H.G., Aschmann H.E., Puhan M.A. Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. Ann Intern Med. 2019 Jan 1;170(1):1-10. doi: 10.7326/M18-1279. www.ncbi.nlm.nih.gov/pubmed/30508425 (дата обращения: 31.01.2021).
52. Mei Z., Liang M., Li L. et al. Effects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. Int J Cancer. 2017 Mar 1;140(5):1068–1081. doi: 10.1002/ijc.30526. www.ncbi.nlm.nih. gov/pubmed/27859151 (дата обращения: 31.01.2021).
53. Wu S.Y., Fang S.C., Shih H.J. et al. Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy. Eur J Cancer. 2019 May;112:109–117. doi: 10.1016/j.ejca.2018.11.032. www.ncbi.nlm.nih.gov/ pubmed/30827745 (дата обращения: 31.01.2021).
54. Chen Y., Li X., Zhang R. et al. Effects of statin exposure and lung cancer survival: A meta-analysis of observational studies. Pharmacol Res. 2019;141:357–365. doi: 10.1016/j.phrs.2019.01.016. www.ncbi.nlm.nih.gov/pubmed/30641276 (дата обращения: 31.01.2021).
55. Brewer HB Jr. Benefit-risk. Am J Cardiol. 2003 Aug 21;92(4B):23K-29K. doi: 10.1016/s0002-9149(03)00779-3. www.ncbi.nlm.nih.gov/pubmed/12948873 (дата обращения: 31.01.2021).
56. Silva M.A, Swanson A.C., Gandhi P.J., Tataronis G.R. Statin-related adverse events: a meta-analysis. Clin Ther. 2006 Jan;28(1):26–35. doi: 10.1016/j.clinthera.2006.01.005. www.ncbi.nlm.nih.gov/pubmed/16490577 (дата обращения: 31.01.2021).
57. Marcum Z.A., Vande Griend J.P., Linnebur S.A. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother. 2012 Aug;10(4):264-71. doi: 10.1016/j.amjopharm.2012.05.002. www.ncbi.nlm.nih. gov/pubmed/22683398 (дата обращения: 31.01.2021).
58. Authors/Task Force Members: Catapano AL., Graham I., De Backer G. et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016 Oct;253:281–344. doi: 10.1016/j.atherosclerosis.2016.08.018. www.ncbi.nlm.nih.gov/pubmed/27594540 (дата обращения: 31.01.2021).
59. Chalasani N., Aljadhey H., Kesterson J. et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004 May;126(5):1287-92. doi: 10.1053/j.gastro.2004.02.015. www.ncbi.nlm.nih.gov/pubmed/15131789 (дата обращения: 31.01.2021).
60. Vuppalanchi R., Teal E., Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci. 2005 Feb;329(2):62-5. doi: 10.1097/00000441200502000-00002. www.ncbi.nlm.nih.gov/pubmed/15711421 (дата обращения: 31.01.2021).
61. Dongiovanni P., Petta S., Mannisto V. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015 Sep;63(3):705-12. doi: 10.1016/j.jhep.2015.05.006. www.ncbi.nlm.nih.gov/pubmed/25980762 (дата обращения: 31.01.2021).
62. Doumas M., Imprialos K., Dimakopoulou A. et al. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. Curr Pharm Des. 2018;24(38):4587–4592. doi: 10.21 74/1381612825666190117114305. www.ncbi.nlm.nih.gov/ pubmed/30652643 (дата обращения: 31.01.2021).
63. Kargiotis K., Athyros V.G., Giouleme O. et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015 Jul 7;21(25):7860-8. doi: 10.3748/wjg.v21.i25.7860. www. ncbi.nlm.nih.gov/pubmed/26167086 (дата обращения: 31.01.2021).
64. Nakahara T., Hyogo H., Kimura Y. et al. Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res. 2012 Nov;42(11):1065-72. doi: 10.1111/j.1872-034X.2012.01034.x. www.ncbi. nlm.nih.gov/pubmed/22583925 (дата обращения: 31.01.2021).